Short answer · Medically reviewed summary · Last updated: 2026-05-08
Acromicric dysplasia is a rare form of skeletal dysplasia first characterized in the late 20th century, defined by severe short stature and distinctive "acromicric" features like small hands and feet. Our medical understanding of acromicric dysplasia has evolved significantly since its initial description, shifting from a purely clinical observation to a precise molecular diagnosis linked to mutations in the FBN2 gene. When was acromicric dysplasia first identified? Acromicric dysplasia was first formally described in the medical literature in 1986 by Dr.
What is the history of Acromicric Dysplasia?
History of Acromicric Dysplasia: when and how it was discovered, and the milestones in research since, medically reviewed.
Acromicric dysplasia is a rare form of skeletal dysplasia first characterized in the late 20th century, defined by severe short stature and distinctive "acromicric" features like small hands and feet. Our medical understanding of acromicric dysplasia has evolved significantly since its initial description, shifting from a purely clinical observation to a precise molecular diagnosis linked to mutations in the FBN2 gene.
When was acromicric dysplasia first identified?
Acromicric dysplasia was first formally described in the medical literature in 1986 by Dr. Carlos A. Maroteaux and colleagues. They distinguished this condition from other skeletal dysplasias by focusing on the unique combination of extreme short stature and the characteristic disproportionately small hands and feet. For many years, acromicric dysplasia was primarily a diagnosis of exclusion, made only after ruling out other more common growth-related disorders.
How has our understanding of the genetics behind acromicric dysplasia changed?
The most significant milestone in the history of acromicric dysplasia occurred in 2011, when researchers identified that it is caused by heterozygous mutations in the FBN2 gene (fibrillin-2). This discovery was revolutionary because it confirmed that acromicric dysplasia belongs to a group of conditions known as fibrillinopathies, which also include conditions like Weill-Marchesani syndrome. This genetic insight replaced older, less accurate clinical classifications and allowed for definitive molecular testing.
What are the major historical milestones in the study of this condition?
- 1986: Initial clinical characterization by Maroteaux et al. defining the core phenotype of acromicric dysplasia.
- 2011: Landmark discovery linking the condition to FBN2 gene mutations.
- Modern Era: Shift toward multidisciplinary management, focusing on growth hormone therapy and orthopedic support for joint issues.
How has patient advocacy shaped the narrative of acromicric dysplasia?
Historically, individuals with acromicric dysplasia often faced diagnostic delays and isolation. The rise of digital health platforms, including DiseaseMaps.org where 3 members have already shared their experiences, has fostered a global community. This connectivity has helped correct historical misconceptions that the condition was merely a variant of idiopathic short stature, ensuring that patients receive specialized care tailored to their specific skeletal needs.
Next steps
- Consult a clinical geneticist to discuss molecular testing for FBN2 mutations.
- Connect with the 3 members of the DiseaseMaps.org community to share lived experiences.
- Request a referral to a pediatric endocrinologist for an evaluation of growth hormone therapy options.
Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult a qualified healthcare professional for diagnosis and treatment.
References
- NIH Genetic and Rare Diseases Information Center (GARD): Acromicric dysplasia.
- Orphanet: Acromicric dysplasia (ORPHA:2167).
- OMIM (Online Mendelian Inheritance in Man): Acromicric Dysplasia (#102370).
- PubMed: "FBN2 mutations in acromicric and geleophysic dysplasias" (Le Goff et al., 2011).
